About Enhancer
| Enhancer ID: | E_00602 |
| Species: | Homo sapiens |
| Position : | chr13:28268000-28270000   |
| Year: | 2022 |
| Title: | Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL |
| Genome Build: | hg19 |
| Enhancer Type: | Promoter |
| Condition: | Disease |
| Disease Name: | B-cell acute lymphoblastic leukemia |
| PMID: | 35316324 |
| MONDO: | MONDO:0004945 |
| Tissue: | Bone Marrow |
| Tissue Ontology ID: | UBERON:0002371 |
| Cell Source: | PDX B-ALL cells |
| CVCL ID: | |
| Cell Type: | patient-derived xenograft B-ALL cell |
| Cell Ontology ID: | CL:0000945 |
| Experiment Type: | Histone modification ChIP-seq, Chromosome conformation capture sequencing, RNA-DNA FISH |
| High Throughput Method: | H3K27ac ChIP-seq, H3K4me3 ChIP-seq, 4C-seq, RNA-seq |
| Low Throughput Method: | Allele-specific expression analysis |
About Target Gene
| Target gene : | CDX2 |
About TF
| TF name : | CDX2 |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| CDX2 | POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | reactome | 10 |
| CDX2 | Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | reactome | 20 |
Enhancer Associated Network
Expression of Target Genes for the Enhancer